The biotechnology sector, as measured by the XBI ETF, dropped significantly during the current market session, caught in a wider market downturn affecting technology and other growth-oriented industries. The Nasdaq Composite saw a steep decline, reportedly driven by investor concerns that the new Democratic majority in Congress could lead to increased regulation and scrutiny of the artificial intelligence sector, particularly regarding data center expansion. This has created a risk-off sentiment for high-beta sectors, including biotech, which is sensitive to shifts in investor appetite for growth.